Spacely AI
BANGKOK, THAILAND / ACCESSWIRE / March 6, 2024 / Spacely AI, a comprehensive interior architecture design platform powered by Generative AI, is excited to close a pre-seed investment from SCB 10X. The funding will fuel Spacely AI's mission to empower everyone with the opportunity to design their own success and position Spacely AI as the go-to platform in spatial design.
Spacely AI Pre Seed Investment from SCB 10X
"SCB 10X is proud to back Spacely AI and their mission to unlock productivity and creativity for designers. Given the powerful breakthroughs in visual-based generative AI, spatial design is an application that will continue to benefit with the rapid advancements of this technology. We will continue to support Spacely AI in identifying the strategic and product priorities for the platform, enriching Spacely AI's proposition from Thailand to the global design community," shared Mukaya (Tai) Panich, Chief Executive Officer and Chief Venture and Investment Officer of SCB 10X.
"The backing from SCB 10X is a partnership that aligns with our vision to transform the spatial design landscape. This underscores our mutual belief in the potential of Generative AI to redefine global design standards," says Paruey Anadirekkul, Chief Executive Officer of Spacely AI.
Spacely AI is expanding their global footprint, serving users from Thailand, United States, Portugal, and several other countries worldwide. They have achieved recognition from the global startup community, winning the second runner-up in the "Tech in Asia 2023 Regional Startup Competition" and emerging as the first runner-up in the "LabLab Stable Diffusion Hackathon 2023".
Forming strategic partnerships with Index Living Mall and Proud Real Estate, Spacely AI's has designed over 1,000,000+ spaces for 120,000+ users worldwide. The platform offers 12+ innovative features, 100+ interior curated premium styles, and supports more than 100+ space types, from interiors to exteriors, providing a comprehensive solution for all spatial design needs.
"In choosing Spacely AI's technology, Index Living Mall aims to precisely capture customer requirements, boost designer productivity, and enhance the customer experience. This platform streamlines our design process, reducing the need for revisions and improving efficiency. It represents a significant step forward in our commitment to service excellence and business growth," said Ekalak Patamasatayasonthi, Senior Vice President Business Development at YOUNIQUE & The Walk Line.
"Our partnership with Spacely AI has enhanced the customer journey, creating unparalleled experiences that truly reflect our brand and our real estate offerings. Their AI-driven designs have created our spaces into interactive canvases, serving as the touchpoints for engagement throughout the customer journey. This enables customers to seamlessly bring their design ideas to reality," stated Pasu Liptapanlop, Director, Proud Real Estate.
Today Spacely AI unveils its new API products made available for enterprises:
- Instant Rendering API: Allows for quick visualization of design concepts, effortlessly bringing ideas to life.
- Smart Recommendation API: Matches your products with customer's designed space based on their preferences, budget, and space.
- Product Visualization API: Provides a visual representation of your products within customer's spaces.
- Precision Space Planning API: Offers detailed space measurement guidance for optimal fit and sizing.
The enterprise's API solutions offer product visualization that enhances both sales and customer experiences.
"The launch of our Enterprise API is a significant leap forward as we set our sights on expanding towards the full spectrum of spatial design, pushing the boundaries of creativity and functionality," adds Paruey Anadirekkul, CEO of Spacely AI.
Join Spacely AI in this exciting journey to redefine spatial design with Generative AI.
Contact Information
Paruey Anadirekkul
CEO
paruey@spacely.ai
Thanatcha Pojthaveekiat
Head of Commercial
thanatcha@spacely.ai
Nawinda Hanrattana
Marketing
nawinda@spacely.ai
Napatsapa Vajarodaya
COO
napatsapa@spacely.ai
SOURCE: Spacely AI
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press release
Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom